Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral t-cell lymphomas

Clinical Lymphoma, Myeloma and Leukemia

Volumn 12, Issue 3, 2012, Pages 180-185

  Talpur, Rakhshandra ^a   Duvic, Madeleine ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Fusion protein; Interleukin 2 receptor; Ontak; Peripheral T cell lymphoma

Indexed keywords

ALBUMIN; CD30 ANTIGEN; DENILEUKIN DIFTITOX;

ADULT; AGED; BACKACHE; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MALE; MYCOSIS FUNGOIDES; NAUSEA; NK T CELL LYMPHOMA; PERIPHERAL T CELL LYMPHOMA; REVIEW; SIDE EFFECT; THYROTOXICOSIS; TREATMENT RESPONSE; VASCULAR DISEASE; VASCULAR LEAK SYNDROME; VOMITING;

EID: 84861028258     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2012.01.011     Document Type: Article

References (25)

1. WHO Classification of tumours of haematopoietic and lymphoid tissues 2008 IARC Lyon, France
2. J. Rodriguez, A. Gutierrez, B. Martinez-Delgado Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets Crit Rev Oncol/Hematol 71 2009 181 198
3. J. Vose, J. Armitage, D. Weisenburger International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes J Clin Oncol 26 2008 4124 4130
4. B. Coiffier, N. Brousse, M. Peuchmaur GELA (Groupe d'Etude des Lymphomes Agressives) Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen Ann Oncol 1 1990 45 50 (Pubitemid 20295054)
5. K.J. Savage Prognosis and primary therapy in peripheral T-cell lymphomas Hematology Am Soc Hematol Educ Program 2008 280 288
6. A.N. Abouyabis, P.J. Shenoy, C. Flowers Response and survival rates in patients with peripheral T-cell lymphoma treated with anthracycline-based regimens: a comprehensive meta-analysis Blood 110 2007 1011a (ASH abstract 3452)
7. S.M. Malik, K. Liu, X. Qiang Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T cell lymphoma: U.S. Food and Drug Administration drug approval summary Clin Cancer Res 16 2010 4921 4927
8. F.M. Foss, P.L. Zinzani, J.M. Vose Peripheral T-cell lymphoma Blood 117 2011 6756 6767
9. M. Duvic, R. Talpur Optimizing denileukin diftitox (Ontak) therapy Futures Oncol 4 2008 457 469
10. R.J. Robb, C.M. Rusk, J. Yodoi Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors Proc Natl Acad Sci U S A 84 1987 2002 2006 (Pubitemid 17054137)
11. R. Talpur, D.M. Jones, A.J. Alencar CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma J Invest Dermatol 126 2006 575 583 (Pubitemid 43255644)
12. J. Nichols, F. Foss, T.M. Kuzel Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies Eur J Cancer 33 1997 S34 S36
13. E. Olsen, M. Duvic, A. Frankel Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma J Clin Oncol 19 2001 376 388 (Pubitemid 32112849)
14. H.M. Prince, M. Duvic, A. Martin Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma J Clin Oncol 28 2010 1170 1177
15. S.R. Stevens, M.S. Ke, E.J. Parry Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT) Arch Dermatol 138 2002 42 48 (Pubitemid 34056233)
16. M. Duvic, E. Hodak, R. Talpur Complete response of a primary cutaneous CD30+ anaplastic large-cell lymphoma to denileukin diftitox Case Studies in Lymphoma 3 2004 3 6
17. K. Vidulich, D. Jones, M. Duvic Cutaneous gamma/delta T-cell lymphoma treated with radiation and denileukin diftitox Clin Lymphoma Myeloma 8 2008 55 58 (Pubitemid 351449720)
18. F. Ghori, K.D. Polder, L.C. Pinter-Brown Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides J Clin Endocrinol Metab 91 2006 2205 2208 (Pubitemid 43855006)
19. R. Talpur, N. Apisarnthanarax, S. Ward Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (Ontak) Leuk Lymphoma 43 2002 121 126 (Pubitemid 34223979)
20. B.Y. Wong, Y. Ma, R. Fitzwilson De novo maintenance therapy with denileukin diftitox (Ontak) in a patient with peripheral T cell lymphoma is associated with prolonged remission Am J Hematol 83 2008 596 598 (Pubitemid 351874881)
21. N.H. Dang, B. Pro, F.B. Hagemeister Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma Br J Haematol 136 2007 439 447 (Pubitemid 46046302)
22. R. Baluna, E.S. Vitetta Vascular leak syndrome: a side effect of immunotherapy J Immunopharmacol 37 1997 117 132 (Pubitemid 27471029)
23. R. Baluna, J. Rizo, B.E. Gordon Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome Proc Natl Acad Sci U S A 96 1999 3957 3962 (Pubitemid 29169018)
24. E.S. Vitetta, M. Stone, P. Amlot Phase I immunotoxin trial in patients with B-cell lymphoma Cancer Res 51 1991 4052 4058
25. F.M. Foss, N. Sjak-Shie, A. Goy Phase II study of denileukin diftitox (Ontak®) with CHOP chemotherapy in patients with newly-diagnosed aggressive T-cell lymphomas, the CONCEPT trial: interim analysis Blood (ASH Annual Meeting Abstracts) 108 2006 2461